Kali Inc (KALY) fair value: what the stock is really worth
As of Sep 18, 2026: fair value of Kali Inc $0.00, price $0.00, upside +0.0%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Kali Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Kali, Inc., doing business as Kali-Extracts, Inc., engages in the research and development of cannabis treatments for various illnesses, diseases, and chronic pain as a symptom of various diagnoses. It provides pharmaceuticals, cannabis extracts, and health and wellness products. The company was formerly known as VLOV Inc. and changed its name to Kali, Inc.
Show more
Kali, Inc., doing business as Kali-Extracts, Inc., engages in the research and development of cannabis treatments for various illnesses, diseases, and chronic pain as a symptom of various diagnoses. It provides pharmaceuticals, cannabis extracts, and health and wellness products. The company was formerly known as VLOV Inc. and changed its name to Kali, Inc. in February 2016. Kali, Inc. is based in Dallas, Texas.
Stock analysis
Kali Inc (KALY) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 18 models at a data quality of 88/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Kali Inc reported revenue of $71.5K in FY2016 versus $88.8M in FY2011, a compound −75.9%/yr. Reported net income was $1.4K in FY2016, compounding −84.2%/yr from FY2011.
Key figures
Market cap $102K · Net margin 1.9% · Return on equity 33.0% · Return on assets (EBIT) 7.0% · Operating margin 28.5% · Revenue growth (YoY) +75.5% · EPS growth (YoY) +124%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 0%, KALY screens cheaper than that median.
Fair Value models
Bear $0.0001Fair Value $0.0001Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−14.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−75.9%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−56.1%
’08
’09
’10
’11
’12
’14
’15
’16
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
19.9% (2011) → 1.9% (2016)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 5/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside+0% · Above median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets23% · Top 25%
Net margin (TTM)20% · Top 25%
Operating margin (TTM)28% · Top 25%
Growth and dividend
Revenue growth76% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)33· sector 14
FUTURE (revenue growth)100· sector 20
PAST (return on equity)0· sector 27
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 32
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Kali Inc Fair Value". https://www.fairvalue-calculator.com/stock/KALY
Frequently asked questions
Is Kali Inc (KALY) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.0001 versus the last price from Sep 18, 2026 of $0.0001, about +0% upside (fairly valued).
What is the fair value of KALY?
Our model-based fair value for Kali Inc is $0.0001 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 18, 2026): $0.0001.
What is the quality score of KALY?
Kali Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kali Inc (KALY)?
Our model-based price target is the fair value of $0.0001 (as of Sep 24, 2026) from 3 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Kali Inc stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus the last price from Sep 18, 2026 of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of Kali Inc (KALY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kali Inc it is $0.0001 per share (as of Sep 24, 2026), against a price of $0.0001. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Kali Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, KALY trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KALY?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Kali Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kali Inc worth?
The market values Kali Inc at about $102K (market capitalisation, as of Sep 24, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of Kali Inc (KALY)?
Balance-sheet figures for Kali Inc (as of Sep 24, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
Which stocks are comparable to Kali Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kali Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 51/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KALY calculated?
We run Kali Inc through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Kali Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kali Inc (KALY)?
The latest price we hold is from Sep 18, 2026 and stands at $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kali Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Kali Inc
How large is the market capitalisation of Kali Inc (KALY)?
The market capitalisation of Kali Inc is $102K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the net margin of Kali Inc (KALY)?
The net margin of Kali Inc is 1.9% (fiscal year 2016). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kali Inc (KALY)?
The return on equity (ROE) of Kali Inc is 33.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kali Inc (KALY)?
On an EBIT basis the return on assets of Kali Inc is 7.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kali Inc (KALY)?
The operating margin of Kali Inc is 28.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kali Inc (KALY)?
Revenue at Kali Inc is growing +75.5% versus a year earlier (3y avg −90.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kali Inc (KALY)?
Earnings per share at Kali Inc are growing +124% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Kali Inc in the live analysis
One click puts Kali Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026